Search results
Results From The WOW.Com Content Network
The ratio of xenon-136 to xenon-135 (or its decay products) can give hints as to the power history of a given reactor and the absence of xenon-136 is a "fingerprint" for nuclear explosions, as xenon-135 is not produced directly but as a product of successive beta decays and thus it cannot absorb any neutrons in a nuclear explosion which occurs ...
Xenon-135 (135 Xe) is an unstable isotope of xenon with a half-life of about 9.2 hours. 135 Xe is a fission product of uranium and it is the most powerful known neutron-absorbing nuclear poison (2 million barns; [1] up to 3 million barns [1] under reactor conditions [2]), with a significant effect on nuclear reactor operation.
Radioactive isotope table "lists ALL radioactive nuclei with a half-life greater than 1000 years", incorporated in the list above. The NUBASE2020 evaluation of nuclear physics properties F.G. Kondev et al. 2021 Chinese Phys. C 45 030001. The PDF of this article lists the half-lives of all known radioactives nuclides.
Xenon-136 is an isotope of xenon that undergoes double beta decay to barium-136 with a very long half-life of 2.11 × 10 21 years, more than 10 orders of magnitude longer than the age of the universe ((13.799 ± 0.021) × 10 9 years). It is being used in the Enriched Xenon Observatory experiment to search for neutrinoless double beta decay.
The minerals detected included sodium carbonate compounds such as trona (sometimes referred to as “soda ash”) that the scientists said had never been observed in other extraterrestrial samples.
Nonetheless, this was the first real compound of any noble gas. The first binary noble gas compounds were reported later in 1962. Bartlett synthesized xenon tetrafluoride (XeF 4) by subjecting a mixture of xenon and fluorine to high temperature. [9] Rudolf Hoppe, among other groups, synthesized xenon difluoride (XeF 2) by the reaction of the ...
Microsoft unveiled Majorana 1, a quantum chip the company says is powered by a new state of matter. The new chip allows for more stable, scalable, and simplified quantum computing, the company says.
A Memorial Sloan Kettering phase 1 clinical trial revealed an immune response in some pancreatic cancer patients. Study co-author Dr. Vinod Balachandran talks about the impact on future cancer care.